Contribute Try STAT+ Today

In a stern letter, the U.S. Office of Special Counsel rebuked the Food and Drug Administration over four instances in which agency officials belatedly downgraded troubling findings at manufacturing plants and also urged the FDA to rethink its approach to oversight of inspections.

The investigating agency cited, in particular, a high-profile episode involving a Merck (MRK)vaccine plant in North Carolina, where a whistleblower tipped off the FDA to numerous sanitary problems. An FDA inspector who subsequently visited the plant maintained the violations were serious enough to warrant action by both the FDA and the drug maker. But his recommendations were minimized by supervisors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.